Q4 2025 Camurus AB Earnings Call Transcript

Feb 12, 2026 / 01:00 PM GMT

Release Date Price: $57.85 (-18.52%)

Transcript

Key Points

Positve

Camurus AB (CAMRF) achieved significant milestones in 2025, strengthening its leadership in opioid dependence treatment.
The company expanded its commercial reach into the US, establishing a firm infrastructure for upcoming product launches.
Oxyesa received regulatory approval for acromegaly in both the EU and the UK, marking a significant product milestone.
Camurus AB (CAMRF) reported strong financial performance with full-year revenues reaching 2.3 billion and profit before tax increasing to just above 0.9 billion.
Brixadi royalties in the US showed strong year-on-year growth of 47%, and increased 82% at constant exchange rate.

Negative

Vividol sales declined temporarily due to foreign exchange headwinds and a change in the UK distribution model.
Despite strong financial performance, the company faces challenges in maintaining momentum in certain markets.
The expansion into the US market requires significant investment, which could impact short-term profitability.
The company is exposed to risks associated with regulatory approvals, as seen with the resubmission of the NDA for alas.
Camurus AB (CAMRF) must navigate competitive pressures in the biopharmaceutical industry, particularly in the US market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CAMX.ST - Camurus AB
Q4 2025 Camurus AB Earnings Call
Feb 12, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Camiros Q4 report 2025.

During the question-and-answer session, participants are able to ask questions by dialing 5 on the telephone keypad. Now we'll hand the conference over to CEO 3 Tiba. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Einar, and hello everyone. Welcome to our 4th quarter earnings call and full year.

As customary, please note our forward-looking statements, which I will assume that you have read.

So moving over to the agenda, we will begin today's call with an introduction and business highlights followed by

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.